Fig. 2.

Prediction-corrected visual predictive check plots for the developed population pharmacokinetic model. Data for the first 16 weeks (a) and the entire time of observation (b) after receiving a single (for healthy volunteers) or the first (for patients) subcutaneous administration of emicizumab are presented. Red solid line indicates the observed median, red dashed lines indicate the observed 5th (lower) and 95th (upper) percentiles, and shaded areas indicate the simulated 95% confidence intervals of the 5th percentile (blue, bottom), median (red, middle), and 95th percentile (blue, top)